Written question asked by Gordon Prentice (Labour) on Monday, 8 January 2001, in the House of Commons. It was due for an answer on Monday, 15 January 2001. It was answered by John Denham (Labour) on Monday, 15 January 2001 on behalf of the Department of Health.

Dept of Health

Question: To ask the Secretary of State for Health, when he expects NICE to make its recommendations on the efficacy of (a) Beta Interferon and (b) Copaxone; and if he will ask NICE to consider the merits of the two drugs separately.

Answer: Mr. Gordon Prentice: To ask the Secretary of State for Health when he expects NICE to make its recommendations on the efficacy of (a) Beta Interferon and (b) Copaxone; and if he will ask NICE to consider the merits of the two drugs separately. [144859] Mr. Denham: We expect the National Institute for Clinical Excellence (NICE) to consult on draft guidance later this year, following the development of further economic modelling on Beta Interferon and glatiramer acetate (Copaxone). Further details can be found on the NICE website at www.nice.org.uk. NICE is giving individual consideration to Beta Interferon and glatiramer acetate.

Secondary information

Type: Written question
Reference: 361 c52W; 144859
Session: 2000-01
Subjects: Cost effectiveness Diseases Medical treatments Prescription drugs Multiple sclerosis National Institute for Clinical Excellence Interferon beta Glatiramer acetate Economic models
Link: View this Written question on www.publications.parliament.uk